Impact of Healthcare Associated Infections on Survival and Treatment Outcomes Among End Stage Renal Disease Patients on Renal Replacement Therapy

Saad Hanif Abbasi1, Raja Ahsan Aftab1*, Pauline Siew Mei Lai2, Soo Kun Lim3 and Ruwaida Nur Zainol Abidin4

1School of Pharmacy, Taylor’s University, Subang Jaya, Malaysia, 2Department of Primary Care Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, 3Department of Medicine (Division of Nephrology), Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, 4Department of Pharmacy, Hospital Serdang, Kajang, Malaysia

Background: Due to frequent hospitalizations, complex dialysis procedures and immune compromising effects of end stage renal disease (ESRD), patients on dialysis are more prone to healthcare associated infections (HCAIs).

Objective: To study the impact of HCAIs on survival and treatment outcomes among ESRD patients on renal replacement therapy (RRT).

Methodology: A multicenter, retrospective study was conducted from June to December 2019 at two public hospitals of Malaysia. ESRD patients with minimum of 6 months on RRT were included, while pregnant patients and patients <18 years were excluded. Multinomial logistic regression was performed to identify risk factors associated with unsuccessful treatment outcomes. Kaplan Meier analysis was performed to study the survival.

Results: A total of 670 records were examined, of which 400 patients were included as per the inclusion criteria. The mean survival time of patients without HCAIs [22.7 (95%CI: 22.1–23.2)] was higher than the patients with HCAIs [19.9 (95%CI:18.8–20.9)]. Poor survival was seen in patients with >2 comorbidities, >60 years of age, low hemoglobin concentration and high C-reactive protein levels. The most frequent treatment outcome was cured [113 (64.9%)], followed by death [37 (21.3%)] and treatment failure [17 (9.8%)]. Advancing age, and low hemoglobin concentration were independent risk factors associated with death, while recurrent HCAIs, use of central venous catheters, and low serum sodium levels were risk factors for treatment failure.

Conclusion: The high burden of HCAIs is a profound challenge faced by patients on RRT, which not only effects the treatment outcomes but also contributes substantially to the poor survival among these patients.

Keywords: healthcare associated infections, end stage renal disease (ESRD), renal replacement therapy (RRT), peritoneal dialysis (PD), hemodialysis (HD), treatment outcome
INTRODUCTION

According to an estimate, the global prevalence of end stage renal disease (ESRD) patients undergoing maintenance hemodialysis is increased by 1.7 times from 1990 to 2010 (Thomas et al., 2015). Due to frequent hospitalizations, complex dialysis procedures and immune compromising effects of ESRD, patients on dialysis are more prone to healthcare associated infections (HCAIs) (Donlon et al., 2011; Albuquerque et al., 2014). Moreover, HCAIs are among the major causes of increased morbidity and mortality among these patients (Gupta et al., 2013). According to the United States renal data system, sepsis mortality was 100–300 times higher for chronic dialysis patients compared to general public (Sarnak and Jaber, 2000). Furthermore, almost 20% of patients on renal replacement therapy (RRT) had at least one episode of sepsis (Sarnak and Jaber, 2000). The recent report of Malaysian dialysis and transplant registry report (Ghazali et al., 2016) suggested that sepsis accounts for 28% of all causes of deaths among patients on dialysis (Ghazali et al., 2016).

Antibiotic treatment failure, which is one of the representatives of antibiotic resistance is increased alarmingly over the past few decades and World Health Organization has declared this a global public health crisis (World Health Organization, 2012). It is still unclear whether the differences in mortality and treatment outcomes among dialysis patients result from differences in patient- and facility related factors, inappropriate, suboptimal, or delayed antibiotic therapy, various complications and comorbid conditions, or other factors. There is a need to better characterize and understand the epidemiology and impact of HCAIs on antibiotic treatment outcomes and patients’ survival, which is not simple owing to different infection types, pathogens’ characteristics and large number of antibiotic treatment options available. Only limited information is available on the factors that contribute to poor clinical outcomes and survival among the high risk ESRD population. The present study was performed to determine the impact of HCAIs on treatment outcomes and survival among ESRD patients on RRT.

METHODOLOGY

Study Setting and Study Design

A multicenter, cross sectional, retrospective study was conducted at two study sites in Malaysia, including the University Malaya Medical Centre, and Serdang Hospital. UMMC is a tertiary hospital, located in Kuala Lumpur, Malaysia. The UMMC services over 900 inpatients and approximately 1,500 outpatients daily. On average, 80–90 patients undergo hemodialysis (HD) in this hospital. Hospital Serdang is a tertiary hospital situated in the Sepang District in Selangor. It has 100 HD patients and more than 300 patients on peritoneal dialysis (PD). Both hospitals are government funded.

Patient Population

ESRD patients who were on either HD or PD for a minimum period of 6 months were included, while patients who were pregnant, <18 years and those who have undergone kidney transplantation were excluded. Data of patients who were diagnosed with ESRD (defined as those classified with the international classification of diseases (ICD)-10-CM code N18.6 for ESRD (Wang and Hoy, 2013)) from 2015 to 2019 were extracted from the hospital’s medical records computerized system. All patients were then screened to see if they fit the study’s inclusion/exclusion criteria. The medical records and laboratory data were reviewed using the hospital’s total hospital information system (THIS) to confirm the diagnosis of any HCAI. All data were collected from the time of initiation of dialysis for each patient till 2019. A data collection form was used to retrieve patient demographics and clinical information.

The sample size required was 400 case records (with 80% power and 95% confidence interval (Raosoft. Sample size calc, 2004). To reduce the risk of selection bias, a simple random sampling technique—a research randomizer (Research Randomizer, 1997) was used. Research randomizer utilizes the total number of patients and the sample size to generate random numbers. Each number was noted, and the patient associated with that number on the list was selected.

Criteria for the Selection of Healthcare Associated Infections

For the purpose of this study, the modified definition from Friedman et al. (2002) was adopted as the initial definition of HCAIs (Friedman et al., 2002), where HCAI is defined as “an infection present at the time of hospital admission or within 48 h of admission, resulting from medical care or treatment in a hospital, primary healthcare setting, nursing home, or patient’s home”. An infection was said to be healthcare associated, if the patient had fulfilled any of the following criteria (Friedman et al., 2002), including 1)received any intravenous therapy, wound care or specialized nursing care at home or through a healthcare agency or had self-administered intravenous therapy in 30 days before the infection, 2)had a hospital visit or received intravenous chemotherapy in the previous 30 days or 3)was hospitalized in an acute care hospital for 2 or more days in the previous 90 days.

Following definitions of treatment outcomes were used in the study (Zelenitsky et al., 2003; Wen et al., 2018; Çilli et al., 2018):

Clinical cure (successful treatment outcome) was defined as resolution of clinical signs and symptoms within 30 days of infection or have negative blood culture after completion of therapy. Death (unsuccessful treatment outcome) was defined as mortality due to any cause during treatment within 2 days (early mortality) or within 2–30 days (late mortality) of a positive blood culture. Treatment failure (unsuccessful treatment outcome) indicated persistent infection or unimproved patient’s clinical status and the need to switch to another antibiotic regimen after 3 days of initial treatment. Finally, defaulted or transferred out patients were those whose treatments were interrupted for any reason or those who were...
transferred to another healthcare facility before completion of the therapy.

**Study Endpoints**

The primary endpoint of the study was the 24 months survival (Etikan et al., 2017) of patients from November 2017 till the completion of medical records viewing, whereas the secondary endpoint was mortality due to any cause during this period. All transferred patients and those who could not be followed up through record viewing were tracked using their contact numbers to get their final status. Any patient with an unidentified final status was not included in the survival analysis. Patients were divided during survival analysis as complete follow-up (alive), primary end point reached (alive), death (dead), transferred out (alive/dead).

**Ethical Considerations**

Ethical approval was obtained from the University Malaya Medical Research Ethics Committee (MREC ID NO: 2019320–7245) and the National Malaysian Research Registry (NMRR-19–777–47089) before the initiation of study.

**Statistical Analysis**

Data were coded into nominal, ordinal and continuous variables using the Statistical Package for Social Sciences version 20.0 (SPSS Inc., Chicago, IL, United States). Kolmogorov–Smirnov test was used to assess the normality of data. Both descriptive and inferential statistics were applied to achieve the study objectives. A descriptive analysis of patients’ data was conducted to examine the variables of interest. All categorical variables were presented as absolute frequencies and percentages, while median and interquartile range were used to present continuous variables as normality could not be assumed. Both Chi-square and Fischer’s exact test were used to assess all associations involving categorical variables. These significantly associated variables were included in regression analysis. As the dependent variable was of categorical type with more than two levels, multinomial logistic regression was used to analyze the relationship between independent variables and unsuccessful treatment outcomes. Both univariate and multivariate multinomial logistic regression were used to identify independent risk factors associated with unsuccessful treatment outcomes. Presence and absence of HCAIs were analyzed against the risk factors associated with unsuccessful treatment outcomes. Both univariate and multivariate multinomial logistic regression were used to identify independent risk factors associated with unsuccessful treatment outcomes. Multinomial logistic regression was used to identify independent risk factors associated with unsuccessful treatment outcomes. Both univariate and multivariate multinomial logistic regression were used to identify independent risk factors associated with unsuccessful treatment outcomes. Multinomial logistic regression was used to identify independent risk factors associated with unsuccessful treatment outcomes. Both univariate and multivariate multinomial logistic regression were used to identify independent risk factors associated with unsuccessful treatment outcomes.

**RESULTS**

Out of 670 patient records identified during database search, 400 patients were included as that fitted the inclusion criteria. Fifty seven out of 400 patients were defaulted or transferred out and their final status was unknown, hence they were excluded from survival analysis. Of the remaining 343 participants, there were 142(41.3%) and 201(58.7%) patients with and without HCAIs, respectively. There were significantly a greater number of deaths [53(37.3%)] in the group of patients with HCAIs, compared to 22(10.9%) deaths in the group without HCAIs (p-value <0.001). Baseline characteristics of participants in both the groups are shown in Table 1.

The total number of deaths during the 24 months follow-up period was n = 53 (37.3%) for patients’ group with HCAIs and n = 22(10.9%) for the group without HCAIs. The mean survival time of patients in the group without HCAIs [22.7(95%CI:22.1–23.3)] was higher than the group with HCAIs [19.9(95%CI:18.8–20.9)] and was found to be statistically significant (p-value <0.001; Figure 1). During the study, a significantly better survival (p-value = 0.001) was observed among patients aged 18–40 years [22.8(95%CI:21.7–23.9)] and 41–60 years [22.5(95%CI:21.7–23.3)] as compared to patients aged >60 years [20.7 (95%CI:19.8–21.5)]. Survival trends of study population are shown in Table 2.

Cox regression was applied for predictors associated with survival among study population. Group of patients with HCAIs (HR 1.4) had poor survival and 1.4-folds increased chances of death than group of patients without HCAIs, but the result was statistically nonsignificant (p = 0.288). Moreover, poor survival was seen among patients with >2 comorbidities, >60 years of age, Low Hb concentration and high CRP levels during 24-months survival analysis. However, during multivariate regression analysis, factors such as more than 2 comorbidities, above 60 years of age, low hemoglobin levels and high C-reactive protein concentration were not found to be significantly associated with survival among ESRD patients with or without HCAIs (Table 3).

**Treatment Outcomes**

There were 174 (43.5%) patients with at least one episode of HCAI. The most prevalent HCAI was catheter related bloodstream infection (CRBSI) [64 (36.8%)], while peritonitis [45 (25.8%)] and pneumonia [37 (21.2%)] were also very common. The most frequent treatment outcome seen in this study was cured [113 (64.9%)], followed by death [37 (21.3%)] and treatment failure 17 (9.8%). Moreover, there were 66 (37.9%) patients with recurrent HCAIs. Clinical and sociodemographic variables, such as age, type of dialysis, recurrent HCAIs, type of vascular access, occurrence of CRBSI, sodium and hemoglobin levels were significantly associated with these treatment outcomes (Table 4).

In univariate multinomial logistic regression, factors such as advancing age (OR = 1.06; 95%CI:1.02–1.1, p-value = 0.001), low serum sodium levels (OR = 2; 95%CI:0.9–4.3, p-value = 0.059) and low blood hemoglobin concentration (OR = 6.8; 95%CI:0.8–52, p-value = 0.066) were significantly associated with higher number of deaths from HCAIs. However, recurrent HCAIs (OR = 37; 95%CI:4.7–291, p-value = 0.001), occurrence of CRBSI (OR = 5.9; 95%CI:1.8–19.4, p-value<0.003), use of CVCs (OR = 8.8; 95%CI:2.8–27, p-value<0.001), and low serum sodium levels (OR = 4.2; 95%CI:1.3–12.8, p-value = 0.011) were more likely to cause treatment failure in patients with HCAIs. During multivariate multinomial logistic regression, advancing age (OR = 1.06; 95%CI:1.02–1.1, p-value = 0.001), and low blood hemoglobin concentration (OR = 9.1; 95%CI:1.1–86, p-value = 0.039) were
found to be independent risk factors for death as a treatment outcome, while recurrent HCAIs (OR = 33; 95%CI:4–282, p-value = 0.001), use of CVCs (OR = 4.2; 95%CI:0.9–18.6, p-value = 0.053) and low serum sodium levels (OR = 3.9; 95% CI:0.9–15, p-value = 0.052) were risk factors associated with treatment failure (Table 5).
The study reported a high prevalence (43.5%) of HCAIs among ESRD disease patients undergoing renal RRT. Among the 174 patients with HCAIs, clinical cure (64.9%) was the most frequent treatment outcome, followed by death (21.3%) and treatment failure (9.8%). Patients’ characteristics such as advancing age, low serum sodium levels and low blood Hb concentration were associated with increased mortality in these patients. Furthermore, recurrent HCAIs, occurrence of CRBSI, use of CVCs, and low serum sodium levels were more likely to cause treatment failure in patients with HCAIs. Multivariate logistic regression showed advancing age, and low blood Hb concentration to be independent risk factors for death as a treatment outcome. Recurrent HCAIs, use of CVCs, and hyponatremia were risk factors associated with treatment failure.

Advancing age has shown to increase the chances of mortality by 1.1-folds. Moreover, within age groups, patients aged 18–40 and 41–60 years had significantly higher mean survival time (22.8 and 22.5 months respectively) than patients aged >60 years (20.7 months). Increased mortality is highly associated with poor functional status and aggregation of clinical comorbidities in elderly patients on RRT (Wright, 2015). According to United States Renal Data System (USRDS) registry, nearly 30% of all older adults (≥65 years) on dialysis died in the year 2015 (Wachterman et al., 2019). Therefore, management of RRT related issues such as maintaining vascular access and infection complications, must be addressed with caution. Clinicians must incorporate screening and treatment strategies for various RRT associated complications in elderly patients, including infections, in their routine plan of care.

Low blood Hb concentration was likely to cause 10-folds increase in mortality in the present study. Similarly, a higher mean survival time of 22.9 months was seen in patients with normal blood Hb concentration compared to mean survival time of 21.1 months in patients with lower blood Hb. Similar results have been shown in the previous studies where higher achieved hemoglobin (Hb) levels were associated with decreased mortality (Volkova and Arab, 2006; Bradbury et al., 2009). According to USRDS, longer the patient’s Hb levels remain <11 g/dl, more are the chances of death (Bradbury et al., 2009). The compromised kidney function and prevalence of malnutrition in ESRD patients on RRT, which is evidenced by reduced blood Hb and hypoalbuminemia, may lead to dysfunction of the immune system and therefore, increase the risk of infections induced mortality (Tang and Chen, 2016). Thus, the provision of nutritional support for patients on RRT is vital to help in improving the immune function and decrease infection related deaths. Moreover, adequate dosing and of epoetin alfa (EPO) is necessary to raise Hb concentration in these patients and in case of poor Hb response to EPO therapy, proper dosage adjustment should be performed by pharmacists and physicians.

Patients with recurrent HCAIs were strongly associated with increased occurrence of treatment failure by 33-folds. Another study identified various factors associated with recurrent CRBSI in HD patients, including inappropriate duration of therapy and inappropriate catheter management, while appropriate antibiotic selection was not found to be associated with recurrent CRBSI (Zhang et al., 2019). Due to these recurrent infections, patients on RRT play a predominant role in the epidemics and outbreaks of antibiotic resistant pathogens, such as vancomycin-resistant enterococci (VRE) and vancomycin-resistant Staphylococcus. 

**DISCUSSION**

Low blood Hb concentration was likely to cause 10-folds increase in mortality in the present study. Similarly, a higher mean survival time of 22.9 months was seen in patients with normal blood Hb concentration compared to mean survival time of 21.1 months in patients with lower blood Hb. Similar results have been shown in the previous studies where higher achieved hemoglobin (Hb) levels were associated with decreased mortality (Volkova and Arab, 2006; Bradbury et al., 2009). According to USRDS, longer the patient’s Hb levels remain <11 g/dl, more are the chances of death (Bradbury et al., 2009). The compromised kidney function and prevalence of malnutrition in ESRD patients on RRT, which is evidenced by reduced blood Hb and hypoalbuminemia, may lead to dysfunction of the immune system and therefore, increase the risk of infections induced mortality (Tang and Chen, 2016). Thus, the provision of nutritional support for patients on RRT is vital to help in improving the immune function and decrease infection related deaths. Moreover, adequate dosing and of epoetin alfa (EPO) is necessary to raise Hb concentration in these patients and in case of poor Hb response to EPO therapy, proper dosage adjustment should be performed by pharmacists and physicians.

Patients with recurrent HCAIs were strongly associated with increased occurrence of treatment failure by 33-folds. Another study identified various factors associated with recurrent CRBSI in HD patients, including inappropriate duration of therapy and inappropriate catheter management, while appropriate antibiotic selection was not found to be associated with recurrent CRBSI (Zhang et al., 2019). Due to these recurrent infections, patients on RRT play a predominant role in the epidemics and outbreaks of antibiotic resistant pathogens, such as vancomycin-resistant enterococci (VRE) and vancomycin-resistant *Staphylococcus*.
### TABLE 2 | Survival trends of study participants through Kaplan-Meier survival analysis.

| Variables                                      | Total no. of participants, (N = 342) | Time, months | Death, n | Mean survival time, months (SE) | 95% CI                  | p-value |
|------------------------------------------------|-------------------------------------|---------------|----------|---------------------------------|------------------------|---------|
| **HCAIs**                                      |                                     |               |          |                                 |                        |         |
| Positive history                               | 142                                 | 24 months     | 53       | 19.9 (0.52)                     | 18.8–20.9              | <.0001  |
| Negative history                               | 201                                 | 24 months     | 22       | 22.7 (0.27)                     | 22.1–23.2              | 0.303   |
| **Gender**                                     |                                     |               |          |                                 |                        |         |
| Male                                           | 184                                 | 24 months     | 44       | 21.1 (0.41)                     | 20.3–21.9              | 0.001   |
| Female                                         | 159                                 | 24 months     | 31       | 21.9 (0.37)                     | 21.2–22.1              |         |
| **Age group**                                  |                                     |               |          |                                 |                        |         |
| 18–40 years                                    | 43                                  | 24 months     | 4        | 22.8 (0.56)                     | 21.7–23.9              | 0.282   |
| 41–60 years                                    | 109                                 | 24 months     | 15       | 22.5 (0.39)                     | 21.7–23.3              |         |
| >60 years                                      | 191                                 | 24 months     | 56       | 20.7 (0.42)                     | 19.8–21.5              |         |
| **Body mass index (kg/m2)* (n = 284)**         |                                     |               |          |                                 |                        |         |
| Under weight (Below 18.5)                      | 24                                  | 24 months     | 8        | 19.7 (1.2)                      | 17.2–22.3              | 0.282   |
| Healthy or normal (18.5—24.9)                 | 110                                 | 24 months     | 27       | 21.6 (0.4)                      | 20.7–22.6              |         |
| Overweight (25—29.9)                           | 97                                  | 24 months     | 17       | 22 (1.4)                        | 21.1–22.9              |         |
| Obese (More than 30)                           | 53                                  | 24 months     | 14       | 20.9 (0.7)                      | 19.3–22.4              |         |
| **Race**                                       |                                     |               |          |                                 |                        |         |
| Malay                                          | 184                                 | 24 months     | 41       | 21.6 (0.36)                     | 20.9–22.3              | 0.357   |
| Chinese                                        | 112                                 | 24 months     | 26       | 21.2 (0.53)                     | 20.1–22.2              |         |
| Indian                                         | 44                                  | 24 months     | 7        | 22.2 (0.66)                     | 20.9–23.5              |         |
| Others                                         | 2                                   | 24 months     | 1        | 14 (7)                          | 0.1–27.8               |         |
| **Type of dialysis**                           |                                     |               |          |                                 |                        |         |
| Hemodialysis                                   | 182                                 | 24 months     | 35       | 21.5 (0.39)                     | 20.7–22.3              | 0.319   |
| Peritoneal dialysis                            | 161                                 | 24 months     | 40       | 21.5 (0.39)                     | 20.7–22.3              | 0.657   |
| **No. of years on dialysis**                   |                                     |               |          |                                 |                        |         |
| 2 or less years                                | 129                                 | 24 months     | 30       | 21.3 (0.49)                     | 20.3–22.2              |         |
| >2 years                                       | 214                                 | 24 months     | 45       | 21.7 (0.33)                     | 21.2–22.3              |         |
| **Type of vascular access**                    |                                     |               |          |                                 |                        |         |
| Arteriovenous fistula (AVF)                    | 94                                  | 24 months     | 12       | 22 (0.54)                       | 21.3–23.1              |         |
| Central venous catheter (CVC)                  | 53                                  | 24 months     | 15       | 20.6 (0.79)                     | 19.7–22.2              |         |
| Tenclof catheter                               | 152                                 | 24 months     | 39       | 21.4 (0.41)                     | 20.6–22.2              |         |
| Multiple accesses                              | 43                                  | 24 months     | 9        | 21.3 (0.66)                     | 20.5–23.2              |         |
| **No. of comorbidities**                       |                                     |               |          |                                 |                        | 0.005   |
| 1 or 2                                         | 152                                 | 24 months     | 23       | 22.5 (0.31)                     | 21.9–23.1              |         |
| More than 2                                    | 191                                 | 24 months     | 52       | 20.7 (0.42)                     | 19.9–21.6              |         |
| **Diabetes**                                   |                                     |               |          |                                 |                        |         |
| Yes                                            | 223                                 | 24 months     | 53       | 21.4 (0.34)                     | 20.8–22.1              | 0.271   |
| No                                             | 120                                 | 24 months     | 22       | 21.6 (0.48)                     | 20.7–22.6              | 0.296   |
| **Hypertension**                               |                                     |               |          |                                 |                        |         |
| Yes                                            | 308                                 | 24 months     | 70       | 21.4 (0.29)                     | 20.89–22               | 0.193   |
| No                                             | 35                                  | 24 months     | 5        | 22.2 (0.80)                     | 20.6–23.8              |         |
| **Hyperlipidemia**                             |                                     |               |          |                                 |                        |         |
| Yes                                            | 64                                  | 24 months     | 18       | 21 (0.64)                       | 19.7–22.2              | 0.489   |
| No                                             | 279                                 | 24 months     | 57       | 21.6 (0.31)                     | 21.22.2                |         |
| **Ischemic heart disease**                     |                                     |               |          |                                 |                        |         |
| Yes                                            | 83                                  | 24 months     | 20       | 20.8 (0.67)                     | 19.5–22.1              | 0.607   |
| No                                             | 260                                 | 24 months     | 55       | 21.7 (0.3)                      | 21.1–22.3              |         |
| **Cerebrovascular accident**                   |                                     |               |          |                                 |                        |         |
| Yes                                            | 22                                  | 24 months     | 4        | 22.5 (0.77)                     | 20.9–24                | 0.035   |
| No                                             | 321                                 | 24 months     | 71       | 21.4 (0.29)                     | 20.9–22                |         |
| **No. of medicines patient was taking** (n = 339) |                               |               |          |                                 |                        | <0.001  |
| Less than 5                                    | 4                                   | 24 months     | 3        | 18 (2.3)                        | 13.3–22.6              |         |
| 5 to 10                                        | 230                                 | 24 months     | 51       | 21.4 (0.34)                     | 20.8–22.1              |         |
| More than 10                                   | 105                                 | 24 months     | 21       | 21.7 (0.49)                     | 20.7–22.6              |         |
| TWBCs                                          |                                     |               |          |                                 |                        |         |
| High                                           | 110                                 | 24 months     | 41       | 19.4 (0.61)                     | 18.2–20.6              |         |
| Normal                                         | 220                                 | 24 months     | 27       | 22.7 (0.25)                     | 22.2–23.2              |         |
| Low                                            | 13                                  | 24 months     | 7        | 18.6 (1.7)                      | 15.2–22                |         |
| Hemoglobin                                     |                                     |               |          |                                 |                        | 0.004   |
| Normal                                         | 70                                  | 24 months     | 6        | 22.9 (0.45)                     | 22.3–23.8              |         |
| Low                                            | 273                                 | 24 months     | 69       | 21.1 (0.32)                     | 20.5–21.8              |         |

(Continued on following page)
Moreover, first reports on isolation of these resistant pathogens involved patients on RRT (Zacharioudakis et al., 2015). Antimicrobial stewardship programs and infection control and prevention strategies should be implemented to discourage inappropriate use and promote rationale use of antibiotics particularly in dialysis population. CRBSIs was the most common HCAI found in this study and use of CVCs was associated with 4.2-folds increase in treatment failure as compared to clinical cure. CRBSIs cause considerable increase in morbidity, mortality and healthcare costs (Sahli et al., 2017). Being part of the normal flora, S. aureus is the most common pathogen identified in these infections (Sahli et al., 2017), and due to the high prevalence of vancomycin-resistant S. aureus in dialysis patients (Zacharioudakis et al., 2015), the chances of treatment failure are considerably high. Empirical therapy with antibiotics against methicillin sensitive S. aureus and methicillin resistant S. aureus should be considered when there is risk of catheter related infection. Furthermore, microbiological profiles of the patients should be carefully monitored to choose optimum empirical therapy.

In 24 months survival analysis, a significantly higher mean survival time of 22.7 months was seen in patients without HCAIs than of 19.9 months in patients with HCAIs. Infection is one major cause of mortality and increases the length of hospitalization in ESRD patients (McDonald et al., 2014). A study conducted in United States showed that 9.6 percent of all the deaths incident dialysis patients were caused by infections (Collins et al., 2015). Moreover, mortality due to septicemia and sepsis is significantly higher for chronic dialysis patients than in general public (Sarnak and Jaber, 2000). Efforts should be made to develop strict infection control policies and prevention strategies to reduce the risk of HCAIs. The exposure of ESRD

| Variable                           | Univariate cox regression analysis | Multivariate cox regression analysis |
|-----------------------------------|-----------------------------------|-------------------------------------|
| History of HCAI                   | Hazard ratio (HR) 1.4, SE 0.3     | p-value 0.288                        |
| >2 comorbidities                  | Hazard ratio (HR) 1.8, SE 0.3     | p-value 0.053                        |
| >60 years of age                  | Hazard ratio (HR) 1.9, SE 0.3     | p-value 0.027                        |
| Low Hemoglobin                    | Hazard ratio (HR) 3.4, SE 0.6     | p-value 0.041                        |
| Low serum sodium                  | Hazard ratio (HR) 1.2, SE 0.2     | p-value 0.459                        |
| High C-reactive protein           | Hazard ratio (HR) 3.1, SE 0.4     | p-value 0.012                        |
| High RBS                          | Hazard ratio (HR) 1.3, SE 0.2     | p-value 0.361                        |

HCAI, healthcare associated infection; RBS, random blood sugar. Bold values mean significant p-values.

| Variables | Total no. of participants, (N = 342) | Time, months | Death, n | Mean survival time, months (SE) | 95% CI | p-value |
|-----------|--------------------------------------|--------------|----------|----------------------------------|--------|---------|
| RBCs* (n = 330)   | Normal 60 24 months 7 22.6 (0.54) | 21.5–23.7 | 0.054 |
|               | Low 270 24 months 63 21.4 (0.31) | 20.8–22.0 | 0.060 |
| Urea* (n = 341)   | High 299 24 months 71 21.4 (0.3) | 20.8–21.9 | 0.001 |
|               | Normal 42 24 months 4 22.6 (0.6) | 21.3–23.9 | 0.001 |
| Sodium         | Normal 228 24 months 38 22.2 (0.3) | 21.6–22.8 | 0.001 |
|               | Low 115 24 months 37 20.2 (0.55) | 19.1–21.3 | 0.001 |
| Total protein* (n = 312) | Normal 178 24 months 1 23.5 (0.45) | 22.6–24.4 | 0.001 |
|               | Low 134 24 months 74 21.2 (0.31) | 20.6–21.8 | 0.001 |
| Random blood sugar* (n = 284)   | High 106 24 months 33 20.6 (0.56) | 19.5–21.7 | 0.001 |
|               | Normal 178 24 months 24 22.4 (0.31) | 21.8–23.1 | 0.001 |
| HbA1c range* (n = 310)            | High 169 24 months 42 21.3 (0.4) | 20.6–22.1 | 0.196 |
|               | Normal 141 24 months 26 21.7 (0.4) | 20.8–22.5 | 0.196 |
| C-reactive protein           | High 212 24 months 66 20.5 (0.4) | 19.7–21.3 | 0.001 |
|               | Normal 127 24 months 9 23.2 (0.28) | 22.6–23.8 | 0.001 |

*Incomplete patient records.
HCAI, healthcare associated infection; TWBCs, total white blood cells; RBCs, red blood cells. Bold values mean significant p-values.
| Demographics and clinical variables associated with treatment outcomes of healthcare associated infections. |
|-------------------------------------------------|
| **Median age in years (IQR)** | 62 (16) | 61 (17) | 66 (16) | 60 (20) | 73 (27) | 0.001 |
| **Gender** | Male | 86 (49.4%) | 53 (46.9 %) | 19 (51.4%) | 10 (58.8%) | 4 (57.1%) | 3.298 |
| | Female | 88 (50.6%) | 60 (53.1%) | 18 (48.6%) | 7 (41.2%) | 3 (42.9%) | 0.690 |
| **Age group** | 18–40 years | 16 (9.2%) | 12 (10.6%) | 2 (5.4%) | 2 (11.8%) | 0 (0.0%) | 0.612 |
| | 41–60 years | 51 (29.3%) | 33.6 (30%) | 6 (16.2%) | 6 (35.3%) | 2 (28.6%) | 0.382 |
| | >60 years | 107 (61.5%) | 63 (55.8%) | 29 (78.4%) | 9 (52.9%) | 5 (71.4%) | 0.039 |
| **Body mass index (kg/m²)** | Under weight (Below 18.5) | 12 (8.3%) | 8 (8.6%) | 4 (12.5%) | 0 (0.0%) | 0 (0.0%) | 0.003 |
| | Healthy or normal (18.5–24.9) | 61 (42.1%) | 37 (39.8%) | 15 (46.9%) | 6 (42.9%) | 3 (60%) | 0.048 |
| | Overweight (25–29.9) | 39 (26.9%) | 26 (28%) | 5 (15.6%) | 6 (42.9%) | 1 (20%) | 0.111 |
| | Obese (More than 30) | 33 (22.8%) | 22 (23.7%) | 8 (25%) | 2 (14.3%) | 1 (20%) |
| **Comorbidities** | Diabetes | 123 (70.7%) | 80 (70.8%) | 23 (62.2%) | 14 (82.4%) | 5 (71.4%) | 0.612 |
| | Hypertension | 160 (91.9%) | 103 (91.2%) | 35 (94.6%) | 15 (88.2) | 7 (100%) | 0.003 |
| | Hyperlipidemia | 38 (21.8%) | 21 (18.6%) | 10 (27%) | 6 (35.3%) | 1 (5.9%) | 0.039 |
| | Ischemic heart disease | 36 (20.68%) | 24 (21.2%) | 7 (18.9%) | 2 (11.8%) | 3 (42.9) | 0.117 |
| | Congestive heart failure | 15 (8.62%) | 13 (11.5%) | 1 (2.7%) | 1 (5.9%) | 0 (0.0%) | 0.003 |
| | Anemia | 13 (7.47%) | 9 (8%) | 2 (5.4%) | 1 (5.9%) | 1 (14.3%) | 0.003 |
| **Infections recurrence** | 66 (37.9%) | 34 (30.1%) | 14 (37.8%) | 16 (94.1%) | 2 (28.6%) | 0.003 |
| **Number of medications patient was taking** | Less than 5 | 2 (1.2%) | 0 (0.0%) | 2 (5.4%) | 0 (0.0%) | 0 (0.0%) | 0.003 |
| | 5 to 10 | 119 (68.8%) | 74 (66.5%) | 28 (75.7%) | 11 (68.8%) | 6 (85.7%) | 0.003 |
| | More than 10 | 52 (30.1%) | 34.5 (31%) | 7 (18.9%) | 5 (31.3%) | 1 (14.3) |
| **No. of years on dialysis** | 2 or less | 75 (43.1%) | 44 (38.9%) | 16 (43.2%) | 10 (58.8%) | 4 (57.1%) | 0.003 |
| | More than 2 | 99 (56.9%) | 69 (61.1%) | 21 (56.8%) | 7 (41.2%) | 3 (42.9%) |
| **Type of dialysis** | Hemodialysis | 101 (58%) | 65 (57.5%) | 18 (48.6%) | 15 (88.2%) | 3 (42.9%) | 0.003 |
| | Peritoneal dialysis | 73 (42%) | 48 (42.5%) | 19 (51.4%) | 2 (11.8%) | 4 (57.1%) |
| **Type of vascular access** | Arteriovenous fistula (AVF) | 27 (15.5%) | 20 (17.9%) | 6 (16.2%) | 0 (0.0%) | 1 (14.3%) | 0.003 |
| | Central venous catheter (CVC) | 47 (26.9%) | 24 (21.4%) | 8 (21.4%) | 12 (70.6) | 2 (28.6%) |
| | Tenckhoff catheter | 69 (39.65%) | 44 (39.3%) | 19 (51.4%) | 2 (11.8%) | 4 (57.1%) |
| | Multiple accessesa | 31 (17.81%) | 24 (21.4%) | 4 (10.8%) | 3 (17.6%) | 0 (0.0%) |
| **Type of HCAI infection** | CRBSI | 64 (36.8%) | 40 (35.4%) | 9 (24.3%) | 13 (76.5%) | 2 (28.6%) | 0.003 |
| | Peritonitis | 45 (25.8%) | 29 (25.7%) | 12 (32.4%) | 1 (5.9%) | 3 (42.9%) | 0.143 |
| | Pneumonia | 37 (21.2%) | 23 (20.4%) | 10 (27%) | 3 (17.6%) | 0 (0.0%) | 0.418 |
| | Bacteremia | 23 (13.2%) | 13 (11.5%) | 6 (16.2%) | 4 (23.5%) | 0 (0.0%) | 0.359 |
| | Exit site infection | 19 (10.9%) | 13 (11.5%) | 2 (5.4%) | 3 (17.6%) | 1 (14.3%) | 0.558 |
| | UTI | 6 (3.4%) | 2 (1.8%) | 3 (8.1%) | 1 (5.9%) | 0 (0.0%) | 0.270 |
| **TWBCs** | Normal | 83 (47.7%) | 50 (44.2%) | 19 (51.4%) | 10 (58.8%) | 3 (42.9%) | 0.003 |
| | High | 82 (47.1%) | 60 (53.1%) | 13 (35.1%) | 6 (35.3%) | 4 (57.1%) | 0.003 |
| | Low | 9 (5.2%) | 3 (2.7%) | 5 (13.5%) | 1 (5.9%) | 0 (0.0%) |
| **Hemoglobin** | Normal | 24 (13.8%) | 18 (15.9%) | 1 (2.7%) | 4 (23.5%) | 2 (28.6%) | 0.003 |
| | Low | 150 (86.2%) | 96 (84.1%) | 36 (97.1%) | 13 (76.5) | 5 (71.4%) | 0.003 |
| **Urea** | Normal | 162 (93.6%) | 104 (91.7%) | 36 (97.3%) | 17 (100%) | 5 (71.4%) | 0.003 |
| | High | 11 (6.4%) | 9 (8.3%) | 1 (2.7%) | 0 (0.0%) | 2 (28.6%) | 0.003 |
| **Sodium** | Normal | 95 (54.6%) | 72 (63.7%) | 17 (45.9%) | 5 (29.4%) | 2 (28.6%) | 0.003 |
| | Low | 79 (45.4%) | 41 (36.3%) | 20 (54.1%) | 12 (70.6) | 5 (71.4%) | 0.003 |

(Continued on following page)
patients to hospitals should be minimized to prevent these infections and in turn reduce mortality.

The survival analysis showed that patients with 2 or less comorbidities have shown a comparatively higher mean survival time (22.5 months) than patients with more than 2 comorbidities (20.7 months). Similar results were seen in patients with normal blood sugar levels (22.4 months) compared to patients with higher blood sugar levels (20.6 months). Several studies have reported that better glycemic control is associated with longer survival in patients on RRT, while poor glycemic control increases mortality due to infections (Shurraw et al., 2011; Ricks et al., 2012). Hence, efficient management of glycemic levels can help to reduce the occurrence of HCAIs and improve overall survival.

Hyponatremia has shown to decrease mean survival time in patients on RRT and was also found to cause increase occurrence of treatment failure. Waikar et al. demonstrated a constant connection between hyponatremia and increased mortality on dialysis, and this enhanced mortality is caused partly due to infectious complications (Waikar et al., 2011). Similarly, hyponatremia is correlated with greater risk of infection-related hospitalizations (Mandai et al., 2013). A study suggested that high concentration of serum sodium improve protective action against pathogens by promoting CD4+ cells

### TABLE 4 | (Continued) Demographics and clinical variables associated with treatment outcomes of healthcare associated infections.

| HbA1c range | Clinical cure (n = 113) | Death (n = 37) | Treatment failure (n = 17) | Defaulted or transferred out (n = 7) | p-value* |
|-------------|------------------------|---------------|---------------------------|--------------------------------------|----------|
| High | 91 (56.5%) | 59 (56.2%) | 17 (50%) | 12 (80%) | 3 (42.9%) |
| Normal | 70 (43.5%) | 48 (43.8%) | 17 (50%) | 3 (20%) | 4 (57.1%) |

| Albumin | Clinical cure (n = 113) | Death (n = 37) | Treatment failure (n = 17) | Defaulted or transferred out (n = 7) | p-value* |
|---------|------------------------|---------------|---------------------------|--------------------------------------|----------|
| Normal | 18 (10.3%) | 16 (14.2%) | 0 (0.0%) | 2 (11.8%) | 1 (14.3%) |
| Low | 156 (89.7%) | 97 (85.8%) | 37 (100%) | 15 (88.2%) | 6 (85.7%) |

| Random blood sugar | Clinical cure (n = 113) | Death (n = 37) | Treatment failure (n = 17) | Defaulted or transferred out (n = 7) | p-value* |
|--------------------|------------------------|---------------|---------------------------|--------------------------------------|----------|
| High | 75 (57.7%) | 46 (51.4%) | 18 (66.7%) | 8 (61.5%) | 2 (40%) |
| Normal | 55 (42.3%) | 39 (45.9%) | 9 (33.3%) | 5 (38.5%) | 3 (60%) |

### TABLE 5 | Multinomial logistic regression for risk factors associated with unsuccessful treatment outcomes.

| HCAIs, healthcare associated infections; CRBSI, catheter related blood stream infections; AVF, Arteriovenous fistula; CVC, central venous catheter. | Odds ratio [95% CI (significance; p-value)] | Odds ratio [95% CI (significance; p-value)] |
|---------------------------------------------------------------|--------------------------------------------|--------------------------------------------|
| Death versus cure | Treatment failure vs cure | Death versus cure | Treatment failure vs cure |
| Age | 1.06 [1.02–1.1] (0.001] | 0.99 [0.96–1.0] (0.887] | 1.06 [1.02–1.1] (0.001] | 0.97 [0.9–1.0] (0.329] |
| Recurrent HCAIs | 1.4 [0.6–3.0] (0.382] | 37 [4.7–291] (0.001] | 1.6 [0.6–3.0] (0.289] | 33 [4–282] (0.001] |
| CRBSI | 0.5 [0.2–1.3] (0.216] | 5.9 [1.8–19.4] (0.003] | 0.9 [0.3–2.7] (0.913] | 2.9 [0.6–12.6] (0.156] |
| Type of dialysis | 0.7 [0.3–1.3] (0.347] | 5.5 [1.2–25] (0.027] | 0.4 [0.1–1.2] (0.130] | 2.6 [0.3–18.7] (0.321] |
| Hemo dialysis | Ref | Ref | Ref | Ref |
| Peritoneal dialysis | 0.4 [0.1–1.3] (0.160] | 0.7 [0.2–2.9] (0.722] | - | - |
| Type of vascular access | 0.8 [0.3–2.4] (0.820] | 8.8 [2.8–27] (<0.001] | 0.9 [0.2–3.4] (0.913] | 4.2 [0.9–18.6] (0.053] |
| AVG | 1.6 [0.7–3.4] (0.200] | 0.2 [0.04–0.9] (0.422] | 1.8 [0.7–4.4] (0.182] | 0.2 [0.03–1] (0.054] |
| CVC | 0.4 [0.1–1.3] (0.160] | 0.7 [0.2–2.9] (0.722] | - | - |
| Tenckhoff catheter | 0.1 [0.01–1.1] (0.066] | 1.6 [0.4–5.5] (0.439] | - | - |
| Multiple accesses | 6.8 [0.8–52] (0.066] | 0.6 [0.1–2.1] (0.439] | 9.8 [1.1–86] (0.039] | 0.8 [0.1–4.2] (0.809] |
| Hemoglobin | 2.7 [0.3–22.9] (0.345] | - | - | - |
| Urea | 0.3 [0.04–2.9] (0.345] | - | - | - |
| Normal | 0.4 [0.2–1] (0.059] | 0.2 [0.07–0.7] (0.011] | 1.6 [0.7–3.7] (0.240] | 3.9 [0.9–15] (0.052] |
| Low | 2 [0.9–4.3] (0.059] | 4.2 [1.3–12.8] (0.011] | - | - |
differentiation into T-helper 17 (T$_h$17) cells, while hyponatremia inhibits T$_h$17 cells (Mandai et al., 2013).

To the best of our knowledge, this is the first study conducted on this topic, however, there were few limitations in our study. Although it was a multicenter study, but the collection of data from only two hospitals limits generalizability of results. To reduce the effect of this limitation to a minimum level, sufficient sample size was used in this study. Secondly, being a retrospective study, only the data present in the patients’ medical records were collected. However, patients record at the hospitals were completed with great care and organization. Additionally, all the laboratory tests were performed using standardized protocols in these hospitals, hence it is unlikely that any event of HCAI remained undiagnosed. Moreover, the authors did their best to make sure that the data was collected with great caution, and all ambiguities were resolved by the help of hospital staff and co-investigators from the hospitals. The third limitation of this study is related to the search of patients. All patients were searched using ICD codes for ESRD, hence there is a chance of skipping any patient that fulfilled the criteria for inclusion but was diagnosed with different ICD code. However, random sampling technique was used in this study to overcome this problem. Finally, the modified version of Friedman’s definition of HCAIs was used in this study. It is possible that using any other definition might affect the results.

CONCLUSION

The high burden of HCAIs is profound challenge faced by patients on RRT, which not only affects the treatment outcomes but also contribute substantially to the poor survival among these patients. Infection control policies and prevention strategies should be implemented to overcome these risk factors. Recurrent infections and use of antibiotics are considerably high among the patients on RRT due to frequent and complex surgical procedures and various comorbid conditions. Therefore, appropriate selection, duration, and use of antibiotics is pivotal to not only improve patients’ clinical outcomes but also to decrease the prevalence antibiotic resistant pathogens. Patient contact with hospitals and other healthcare settings should be kept to minimum to reduce the risk of infections, and hence improving clinical outcomes and survival among ESRD patients. Future prospective studies and randomized control trials should provide a narrow focus on antibiotic therapy, treatment outcomes and their associated risk factors, which will further clarify the burden and effect of these contributing factors.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by 1) University Malaya Medical Research Ethics Committee (MREC ID NO: 2019320–7245) 2) National Malaysian Research Registry (NMRR–19–777–47089). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements. Written informed consent was not obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTION

SA and RA have planned the study. SA conducted the survey and both SA and RA drafted the first version of the manuscript. PL, SL, and RZA verified the validity of statistical analysis and critically reviewed the manuscript. All authors have been involved in all stages of the manuscript. Finally, all authors read and approved the submission of final manuscript.

ACKNOWLEDGMENTS

The authors would like to acknowledge the Centre for Higher Degrees by Research (CHDR) of Taylor’s University for providing fellowship for SA. The authors wish to pay gratitude to RA, who worked as a co-investigator during the study. The authors would also like to thank the staff members of University of Malaya Medical Centre and Serdang hospital as well as members of Clinical Research Committee (CRC) for providing their support in data retrieval phase. This publication paper is funded by Taylor’s University.

REFERENCES

Albuquerque, S. E., Cavalcante, R. S., Ponce, D., and Fortaleza, C. M. (2014). Epidemiology of Healthcare-Associated Infections Among Patients from a Hemodialysis Unit in southeastern Brazil. Braz. J. Infect. Dis. 18 (3), 327–330. doi:10.1016/j.bjid.2013.10.001

Bradbury, B. D., Danese, M. D., Gleson, M., and Critchlow, C. W. (2009). Effect of Epoetin Alfa Dose Changes on Hemoglobin and Mortality in Hemodialysis Patients with Hemoglobin Levels Persistently below 11 g/dL. Cxan 4 (3), 630–637. doi:10.2215/cjn.03580708

Gilli, A., Sayner, A., Çelenk, B., Şakar-Coşkun, A., Kılıç, O., Hazar, A., et al. (2016). Antibiotic Treatment Outcomes in Community-Acquired Pneumonia. Turk J. Med. Sci. 48 (4), 730–736. doi:10.3906/sag-1709-144

Collins, A. J., Foley, R. N., Gilbertson, D. T., and Chen, S.-C. (2015). United States Renal Data System Public Health Surveillance of Chronic Kidney Disease and End-Stage Renal Disease. Kidney Int. supplements 5 (1), 2–7. doi:10.1038/kisp.2015.2

Donlon, S., Redmond, A., McCann, M., and Einarsdottir, H. (2011). Prevention of Infection in Patients with Chronic Kidney Disease Part III: Surveillance and Auditing in a Renal Care Environment. J. Ren. Care 37 (3), 167–173. doi:10.1111/j.1755-6686.2011.00251.x
